Framework for Social Justice in Biotechnology Governance

1. Introduction

Social justice in biotechnology governance refers to the development and regulation of biotechnological innovations in a manner that ensures equality, fairness, accessibility, human dignity, and protection of fundamental rights. Biotechnology includes genetic engineering, gene editing, stem-cell research, reproductive technologies, genomic databases, synthetic biology, and genetically modified organisms. Although these technologies offer significant benefits, they may also create social inequalities when access, risks, and economic benefits are distributed unfairly.

A proper governance framework must ensure that biotechnology serves the interests of society as a whole rather than only wealthy individuals, private corporations, or technologically advanced countries. It must also protect vulnerable communities from discrimination, exploitation, and involuntary participation in scientific experiments.

In India, the framework is supported by the Constitution, environmental legislation, biomedical research guidelines, and judicial decisions concerning equality, dignity, privacy, and informed consent.

2. Constitutional and Legal Foundations

The Indian Constitution provides the fundamental basis for social justice in biotechnology governance.

Article 14 – Equality Before the Law: Article 14 requires equal protection of the laws and prohibits arbitrary state action. Biotechnology policies should not discriminate against individuals because of their genetic characteristics, disability, socioeconomic background, or other legally protected circumstances.

Article 21 – Right to Life and Personal Liberty: Article 21 protects life, dignity, privacy, and personal autonomy. Genetic testing, reproductive interventions, and biomedical experimentation must respect individual autonomy and bodily integrity.

Article 15 – Prohibition of Discrimination: Article 15 prohibits specified forms of discrimination by the State. Its equality principles are relevant to ensuring that biotechnology policies do not reinforce structural disadvantages.

Directive Principles of State Policy: Articles 38 and 39 encourage the State to promote social welfare, reduce inequalities, and protect the interests of disadvantaged sections. Article 47 also supports public-health improvement.

Together, these provisions establish that biotechnology governance must balance scientific advancement with equality, individual freedom, public health, and social welfare.

3. Core Principles of the Social Justice Framework

A. Equitable Access to Biotechnology

Essential biotechnology-based healthcare, including genetic screening, appropriate gene therapies, and diagnostic services, should be accessible without unfair financial or geographical barriers. Public funding, affordable pricing, transparent licensing, and stronger public healthcare infrastructure can help reduce inequalities.

B. Informed Consent and Individual Autonomy

Researchers and healthcare providers must explain the purpose, risks, benefits, alternatives, and potential consequences of biotechnology procedures. Consent must be voluntary and based on adequate information. Special safeguards are necessary for children, persons with impaired decision-making capacity, and economically vulnerable research participants.

C. Protection Against Genetic Discrimination

Genetic information may reveal predispositions to particular diseases and other sensitive characteristics. Governance rules should protect this information against unauthorized disclosure and unfair use in employment, insurance, education, or public services. Genetic differences must not become a basis for social exclusion.

D. Fair Distribution of Benefits and Risks

The benefits of biotechnology should not be concentrated among corporations or wealthy populations while marginalized communities bear environmental, health, or economic risks. Fair governance requires public consultation, transparent benefit-sharing arrangements, and accessible complaint mechanisms.

E. Protection of Vulnerable Communities

Indigenous peoples, rural communities, economically disadvantaged groups, and populations contributing biological samples require meaningful participation in decisions affecting them. Their knowledge, biological resources, and traditional practices must not be exploited without appropriate safeguards and legally required consent or benefit-sharing.

4. Regulatory and Institutional Mechanisms

An effective framework requires coordinated action by government agencies, research institutions, healthcare providers, and independent regulatory bodies.

A. Ethical Review Committees: Institutional Ethics Committees should evaluate research proposals involving human participants, genetic testing, and biological samples. They must assess scientific validity, informed consent, potential harm, participant selection, and protection of vulnerable groups.

B. Scientific and Environmental Regulation: The Environment (Protection) Act, 1986, and the Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells, 1989, provide an important regulatory basis for activities involving genetically engineered organisms. Risk assessment and environmental safeguards should prevent biotechnology-related harm to communities and ecosystems.

C. Data Protection: Genetic and medical information should be collected for legitimate purposes, protected through appropriate security measures, and accessed only by authorized persons. The Digital Personal Data Protection Act, 2023, is relevant to digital personal data, subject to its scope, commencement, and applicable provisions.

D. Public Participation: Governments should conduct transparent consultations before approving biotechnology policies with significant social consequences. Public participation is particularly important when research affects indigenous communities, agricultural workers, patients, or the environment.

5. Important Case Laws

A. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

Citation: (2017) 10 SCC 1.

The Supreme Court unanimously recognized privacy as a fundamental right under the Constitution, particularly Article 21. The judgment connected privacy with dignity, autonomy, personal choice, and informational self-determination.

PRIVACY

+1

Relevance: This judgment provides a constitutional foundation for protecting genomic databases, genetic test results, and medical research records. Biotechnology governance must ensure that the collection and use of personal genetic information are legally justified and subject to appropriate safeguards.

B. Samira Kohli v. Dr. Prabha Manchanda (2008)

Citation: (2008) 2 SCC 1.

The Supreme Court emphasized that valid medical consent must be voluntary, informed, and given by a competent person. Consent for one medical procedure does not automatically authorize a substantially different procedure.

Indian Kanoon

+1

Relevance: The principles apply to biotechnology interventions, genetic testing, and experimental treatments. Researchers must explain the nature, purpose, risks, benefits, and alternatives of an intervention before obtaining consent.

C. Common Cause v. Union of India (2018)

Citation: (2018) 5 SCC 1.

The Supreme Court recognized the validity of advance medical directives and upheld the principle that competent individuals may exercise autonomy concerning medical treatment, including decisions about end-of-life care.

Indian Kanoon

Relevance: The decision reinforces the importance of bodily autonomy and dignity in medical decision-making. These values are relevant when developing ethical safeguards for biotechnology and experimental medical interventions.

D. Suchita Srivastava v. Chandigarh Administration (2009)

Citation: (2009) 9 SCC 1.

The Supreme Court recognized reproductive choice as an aspect of personal liberty under Article 21 and emphasized the importance of a woman's reproductive autonomy.

Relevance: The judgment supports a rights-based approach to reproductive biotechnology, including assisted reproductive procedures and related medical decisions. It cautions against replacing an individual's autonomy with institutional or societal preferences.

6. Implementation Challenges

The principal challenges include unequal access to advanced treatments, high research and development costs, weak public awareness, inadequate genetic privacy protections, and unequal bargaining power between research institutions and participants. Commercial interests may also conflict with public welfare.

These challenges can be addressed through stronger public investment, affordable treatment policies, transparent licensing, independent ethical oversight, public education, and accessible legal remedies. Regulatory authorities should periodically review emerging technologies and assess their effects on disadvantaged communities.

7. Recommendations for an Effective Framework

The following measures can strengthen social justice in biotechnology governance:

Establish clear legal safeguards against misuse of genetic and medical information.

Improve access to essential biotechnology-based healthcare through public funding and equitable pricing.

Require meaningful informed consent and independent ethical review for human research.

Introduce effective grievance-redressal mechanisms and appropriate compensation for research-related harm.

Ensure fair benefit-sharing when biological resources or traditional knowledge are used commercially.

Require transparent risk assessments and public consultation for technologies with significant environmental or social effects.

Promote international cooperation to prevent technological inequalities between developed and developing countries.

8. Conclusion

Social justice in biotechnology governance requires more than scientific regulation; it requires a commitment to equality, dignity, autonomy, privacy, and fair distribution of benefits. The Indian Constitution, particularly Articles 14 and 21, provides a strong foundation for protecting individuals against discriminatory and arbitrary biotechnology practices. Judicial decisions such as Puttaswamy, Samira Kohli, Common Cause, and Suchita Srivastava reinforce the importance of privacy, informed consent, bodily integrity, and personal autonomy.

Ultimately, biotechnology should advance public welfare without deepening existing social inequalities. A just governance framework must ensure that scientific innovation remains ethically responsible, legally accountable, environmentally sustainable, and accessible to all sections of society.